Table I.
Demographic data of asthmatic and control participants
| Asthma Based on Steroid Dose | ||||||
|---|---|---|---|---|---|---|
| Control (n = 13) | Asthma (n = 27) | p Value | No/Low Dose (n = 8) | High Dose (n = 19) | p Value | |
| Demographics | ||||||
| Age, y | 38.3 (3.3) | 45.3 (2.8) | 0.11 | 38.0 (5.9) | 48 (2.8) | 0.08 |
| Gender, female/male (n) | 9/4 | 21/6 | 0.55 | 7/1 | 14/5 | 0.43 |
| Race, African/others/White | 2/0/11 | 10/2/15 | 0.23 | 3/0/5 | 7/2/10 | 0.81 |
| Ethnicity, Hispanic/no Hispanic | 0/13 | 2/25 | 0.31 | 0/8 | 2/17 | 0.19 |
| Severity | 63 (17) | 0 (0) | 89 (17) | 0.0001 | ||
| Lung functions | ||||||
| FEV1, % | 73 (4) | 87 (7) | 69 (4) | 0.022 | ||
| FEV1/FVC, % | 82 (3) | 88 (6) | 80 (3) | 0.263 | ||
| Asthma medication | ||||||
| High-dose inhaled steroids, % (n) | 60 (16) | 0 (0) | 84 (16) | 0.0001 | ||
| Systemic steroids, % (n) | 15 (4) | 0 (0) | 21 (4) | 0.159 | ||
| Total high-dose steroids, % (n) | 70 (19) | 0 (0) | 84 (16) | 0.0001 | ||
| Th2-related markers | ||||||
| Blood eosinophils, % | 2.8 (0.3) | 4.0 (0.5) | 2.4 (0.3) | 0.016 | ||
| FENO, ppb | 29 (3.8) | 41 (12) | 26 (3.2) | 0.09 | ||
| IgE, log kU/l | 2.3 (0.1) | 2.0 (0.1) | 2.5 (0.1) | 0.02 | ||
| Th17-related markers | ||||||
| IL-17A, pg/ml | 30.4 (3.1) | 53.5 (8.9) | 0.019 | 45.0 (10.2) | 57.2 (12.0) | 0.45 |
| LCN2, ng/ml | 152 (7) | 160 (7) | 0.418 | 147 (8) | 166 (10) | 0.14 |
| SAA1, ng/ml | 15.6 (0.4) | 18.6 (0.7) | 0.0003 | 17.4 (0.8) | 19.1 (0.8) | 0.14 |
| Blood neutrophils, % | 59 (2) | 58 (3) | 59 (2) | 0.82 | ||
| Sputum neutrophils, % | 41 (7) | 16.7 (8) | 45 (7) | 0.038 | ||
| CRP, µg/ml | 1.18 (0.2) | 2.07 (0.2) | 0.009 | 2.1 (0.4) | 2.1 (0.3) | 0.89 |
Data are represented as mean (SEM). FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.